viewBenchmark Holdings PLC

Benchmark Holdings says licensing talks hit by delays

The aquaculture health group said it will accelerate the programme of disposals and structural efficiencies

Benchmark Holdings PLC -
Conditions in the shrimp market have been challenging in 2019

Benchmark Holdings PLC said it does not expect to complete a commercial licensing deal before its September year-end.

As a result, the aquaculture health group is accelerating the programme of disposals and structural efficiencies.

The discussions with third parties about licensing its non-core animal vaccines have been subject to delays, Benchmark said.

Conditions in the shrimp and seabass markets have been challenging in 2019 after a record shrimp harvest last year has forced customers to cut production, which has knocked demand for products such as fish feed, vaccines and water treatments.

The company is in the midst of a five-year strategy to drive growth and profitability.

Quick facts: Benchmark Holdings PLC

Price: 41 GBX

Market: AIM
Market Cap: £273.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Benchmark Holdings PLC named herein, including the promotion by the Company of Benchmark Holdings PLC in any Content on the Site, the Company...



Benchmark Holdings' Peter George says sale of its vaccine facility is a...

Benchmark Holdings PLC's (LON:BMK) chairman Peter George speaks to Proactive London's Andrew Scott soon after agreeing to sell its vaccine manufacturing assets at its facility in Braintree, UK to Cell and Gene Therapy Catapult. George says he's pleased that Benchmark has been able to be part of...

2 weeks, 5 days ago

2 min read